← Insider buys

STIM

Neuronetics, Inc. · Healthcare

Insiders bought $860K of Neuronetics, Inc. in the last 12 months

1 insider bought on 4 days.

$860KBought, 12 mo
$181KSold, 12 mo
$160.8MMarket cap

STIM over the last year

Insider buy filed (4 days)

Largest buyers, last 12 months

STIM after insider buys

3 months after each buy, from the first price a copier could get.

+36.8%Average
+30.1 ptsVs S&P 500
5 of 8Higher

8 buys since 2018 with 3 months of prices.

Every filing

84 insider filings since 2018, newest first

STIMSell

William Andrew Macan · SVP, General Counsel, CCO and Secretary

$33K−3.0%Mar 9
STIMSell

William Andrew Macan · SVP, General Counsel, CCO and Secretary

$41K−5.0%Jan 25
STIMSell

Stephen Furlong · CFO

$63K−7.0%Jan 25
STIMBuy

Robert Cascella · Director

$61K+59.0%Nov 24
STIMSell

Bruce Joseph Shook · Director

$41K−21.0%Nov 16
STIMBuy

Robert Cascella · Director

$101K+146.0%Aug 31
STIMSell

Stephen Furlong · CFO

$86K−3.0%Jul 30
STIMSell

Keith J Sullivan · President and CEO

$686K−7.0%Jul 19
STIMSell

William Andrew Macan · SVP, General Counsel, CCO and Secretary

$38K−1.0%Jul 9
STIMSell

Stephen Furlong · CFO

$37K−1.0%Jun 8
STIMSell

Sheryl L Conley · Director

$87K−14.0%Jun 3
STIMSell

Bruce Joseph Shook · Director

$203K−34.0%Jun 1
STIMSell

Sheryl L Conley · Director

$94K−13.0%Jun 1
STIMSell

Stephen Furlong · CFO

$458K−11.0%May 24
STIMSell

Gregory Harper · VP of Prod. Dev., Operations

$81K−3.0%Mar 11
STIMSell

Stephen Furlong · CFO

$95K−2.0%Mar 11
STIMSell

William Andrew Macan · SVP, General Counsel, CCO and Secretary

$125K−4.0%Mar 11
STIMSell

Keith J Sullivan · President and CEO

$820K−6.0%Feb 9
STIMSell

Keith J Sullivan · President and CEO

$430K−4.0%Jan 28
STIMSell

Gregory Harper · VP of Prod. Dev., Operations

$54K−2.0%Jan 25
STIMSell

Stephen Furlong · CFO

$138K−3.0%Jan 25
STIMSell

William Andrew Macan · SVP, General Counsel, CCO and Secretary

$270K−6.0%Jan 25
STIMBuy

Brian E Farley · Director

$113K+30.0%Mar 16
STIMBuy

Stephen Furlong · VP and CFO

$50K+10.0%Mar 11
STIMSell

Christopher Thatcher · President and CEO

$215K−27.0%Sep 6
STIMSell

Daniel Guthrie · Chief Commercial Officer

$54K−7.0%May 23
STIMSell

Peter Donato · VP and CFO

$128K−29.0%May 14
STIMSell

Peter Donato · VP and CFO

$352K−44.0%May 13
STIMSell

Christopher Thatcher · President and CEO

$252K−21.0%Apr 8
STIMSell

Peter Donato · VP and CFO

$424K−65.0%Mar 11
STIMBuy

Glenn P Muir · Director

$680KJul 5
STIMBuy

Wilfred E Jaeger · Director

$113KJul 5
STIMBuy

Daniel Guthrie · Chief Commercial Officer

$26K+4.0%Jul 5
STIMBuy

Stephen M Campe · Director

$170KJul 5
About Neuronetics, Inc.

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.